Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25094624 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Claudia Piombino und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy. Hauptthemen laut MEDLINE: Recombinational DNA Repair, Prostatic Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes. The recent approval of olaparib has paved the way to precision medicine for the treatment of metastatic prostate cancer with PARP inhibitors in this subset of patients, especially in the case of BRCA1 or BRCA2 pathogenic/likely pathogenic variants. In face of this new therapeutic opportunity, many issues remain unsolved. This narrative review aims to describe the relationship between homologous recombination repair deficiency and prostate cancer, the techniques used to determine homologous recombination repair status in prostate cancer, the crosstalk between homologous recombination repair and the androgen receptor pathway, the current evidence on PARP inhibitors activity in metastatic prostate cancer also in homologous recombination repair-proficient tumors, as well as emerging mechanisms of resistance to PARP inhibitors. The possibility of combination therapies including a PARP inhibitor is an attractive option, and more robust data are awaited from ongoing phase II and phase III trials outlined in this manuscript.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy.
- Clinical Trials Office, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, 41124 Modena, Italy.
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, 41124 Modena, Italy.
ORCID-Profile: Claudia Piombino, Luciana Mastrodomenico, Massimo Dominici
Zitieren
APA
Piombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D'Agostino, E., Pirola, M., Bacchelli, F., Baldessari, C., Baschieri, M. C., Dominici, M., Sabbatini, R., & Vitale, M. G. (2024). Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094624
Vancouver
Piombino C, Pipitone S, Tonni E, Mastrodomenico L, Oltrecolli M, Tchawa C, et al. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094624
BibTeX
@article{Piombino2024,
author = {Piombino, Claudia and Pipitone, Stefania and Tonni, Elena and Mastrodomenico, Luciana and Oltrecolli, Marco and Tchawa, Cyrielle and Matranga, Rossana and Roccabruna, Sara and D'Agostino, Elisa and Pirola, Marta and Bacchelli, Francesca and Baldessari, Cinzia and Baschieri, Maria Cristina and Dominici, Massimo and Sabbatini, Roberto and Vitale, Maria Giuseppa},
title = {Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25094624}
}
EUVIMED